Provectus Biopharmaceuticals (PVCT) Short Interest Ratio & Short Volume → Nvidia is Pivoting to Solve Big Tech’s $1 Trillion Problem (From Weiss Ratings) (Ad) Free PVCT Stock Alerts $0.17 -0.01 (-3.30%) (As of 05/31/2024 08:51 PM ET) Add Compare Share Share Short InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest Provectus Biopharmaceuticals Short Interest DataCurrent Short Interest500 sharesPrevious Short Interest142,600 sharesChange Vs. Previous Month-99.65%Dollar Volume Sold Short$97.15Short Interest Ratio0.0 Days to CoverLast Record DateMay 15, 2024Outstanding Shares419,520,000 sharesPercentage of Shares Shorted0.00%Today's Trading Volume65,700 sharesAverage Trading Volume278,966 sharesToday's Volume Vs. Average24% Short Selling Provectus Biopharmaceuticals ? Sign up to receive the latest short interest report for Provectus Biopharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartPVCT Short Interest Over TimePVCT Days to Cover Over TimePVCT Percentage of Float Shorted Over Time Ad Wealthpin ProThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy.Click here to get all the information about it. Provectus Biopharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/15/2024500 shares $97.15 -99.7%N/A0 $0.19 4/30/2024142,600 shares $28,377.40 +127.8%N/A0.4 $0.20 4/15/202462,600 shares $10,485.50 -67.2%N/A0.1 $0.17 3/31/2024190,800 shares $34,887.78 +1,700.0%N/A0.3 $0.18 3/15/202410,600 shares $2,299.14 -85.7%N/A0 $0.22 2/29/202474,000 shares $11,003.80 -4.0%N/A0.2 $0.15 Get the Latest News and Ratings for PVCT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Provectus Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 2/15/202477,100 shares $10,470.18 +1,780.5%N/A0.2 $0.14 1/15/202416,300 shares $1,677.27 -50.6%N/A0.1 $0.10 12/31/202333,000 shares $3,168.00 +89.7%N/A0.1 $0.10 12/15/202317,400 shares $1,896.60 +3.0%N/A0 $0.11 11/30/202316,900 shares $2,535.00 -46.5%N/A0 $0.15 11/15/202331,600 shares $4,740.00 +179.7%N/A0 $0.15 10/31/202311,300 shares $904.00 +2,160.0%N/A0 $0.08 10/15/2023500 shares $35.00 No ChangeN/A0 $0.07 9/30/2023500 shares $42.25 -94.8%N/A0 $0.08 9/15/20239,600 shares $943.68 +100.0%N/A0.1 $0.10 8/31/20234,800 shares $489.60 -46.1%N/A0 $0.10 8/15/20238,900 shares $845.50 +1,680.0%N/A0 $0.10 7/31/2023500 shares $54.45 -97.8%N/A0 $0.11 7/15/202322,300 shares $2,796.42 -64.6%N/A0.1 $0.13 6/30/202363,000 shares $7,125.30 +63.6%N/A0.1 $0.11 6/15/202338,500 shares $4,581.50 +7,600.0%N/A0.1 $0.12 5/31/2023500 shares $67.95 -99.4%N/A0 $0.14 5/15/202381,400 shares $11,387.86 +13,466.7%N/A0.4 $0.14 4/30/2023600 shares $80.22 -81.3%N/A0 $0.13 4/15/20233,200 shares $489.60 -96.4%N/A0 $0.15 3/31/202389,000 shares $14,685.00 +88,900.0%N/A0.3 $0.17 3/15/2023100 shares $15.40 -99.9%N/A0 $0.15 2/28/2023116,600 shares $18,772.60 +3,051.4%N/A0.3 $0.16 2/15/20233,700 shares $395.53 -89.5%N/A0 $0.11 1/31/202335,200 shares $4,509.12 +262.9%N/A0.1 $0.13 1/15/20239,700 shares $1,286.71 +9,600.0%N/A0 $0.13 12/30/2022100 shares $10.83 -99.0%N/A0 $0.11 12/15/202210,000 shares $1,099.00 -66.6%N/A0 $0.11 11/30/202229,900 shares $2,780.70 -45.5%N/A0 $0.09 11/15/202254,900 shares $2,843.82 +54,800.0%N/A0.1 $0.05 10/31/2022100 shares $5.00 No ChangeN/A0 $0.05 10/15/2022100 shares $4.85 No ChangeN/A0 $0.05 9/30/2022100 shares $4.90 -99.6%N/A0 $0.05 9/15/202225,500 shares $1,351.50 +8.5%N/A0.1 $0.05Nvidia is Pivoting to Solve Big Tech’s $1 Trillion Problem (Ad)Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …Find out details on these three critical Nvidia partners immediately. 8/31/202223,500 shares $1,280.75 +2,511.1%N/A0.1 $0.05 8/15/2022900 shares $49.50 +80.0%N/A0 $0.06 7/31/2022500 shares $29.00 +400.0%N/A0 $0.06 7/15/2022100 shares $5.99 -99.6%N/A0 $0.06 6/30/202226,200 shares $1,419.28 +26,100.0%N/A0.1 $0.05 6/15/2022100 shares $5.30 -96.8%N/A0 $0.05 5/31/20223,100 shares $186.00 -54.4%N/A0 $0.06 5/15/20226,800 shares $357.68 +3,300.0%N/A0 $0.05 4/30/2022200 shares $12.28 +100.0%N/A0 $0.06 4/15/2022100 shares $5.86 No ChangeN/A0 $0.06 3/31/2022100 shares $6.74 No ChangeN/A0 $0.07 3/15/2022100 shares $6.92 -96.7%N/A0 $0.07 2/28/20223,000 shares $206.70 +2,900.0%N/A0 $0.07 2/15/2022100 shares $7.00 -98.7%N/A0 $0.07 1/31/20227,700 shares $500.50 -85.4%N/A0 $0.07 1/15/202252,600 shares $3,682.00 +39.2%N/A0.1 $0.07 12/31/202137,800 shares $2,079.00 +37,700.0%N/A0 $0.06 12/15/2021100 shares $5.03 -93.8%N/A0 $0.05 11/30/20211,600 shares $85.76 -61.0%N/A0 $0.05 11/15/20214,100 shares $213.61 +4,000.0%N/A0 $0.05 10/29/2021100 shares $5.62 -99.9%N/A0 $0.06 10/15/202190,700 shares $5,587.12 -24.6%N/A0.4 $0.06 9/30/2021120,300 shares $7,819.50 +55.8%N/A0.3 $0.07 9/15/202177,200 shares $4,863.60 -45.4%N/A0.2 $0.06 8/31/2021141,300 shares $8,619.30 -29.4%N/A0.1 $0.06 8/13/2021200,200 shares $13,913.90 -22.3%N/A0.5 $0.07 7/30/2021257,500 shares $17,896.25 +29.7%N/A1 $0.07 7/15/2021198,600 shares $13,902.00 +13.6%N/A0.4 $0.07 6/30/2021174,900 shares $11,980.65 -3.6%N/A0.7 $0.07 6/15/2021181,500 shares $12,668.70 -10.4%N/A0.3 $0.07 5/28/2021202,600 shares $14,911.36 +9.0%N/A0.5 $0.07 5/14/2021185,800 shares $12,430.02 +16.1%N/A0.6 $0.07 4/30/2021160,000 shares $10,400.00 No ChangeN/A0.3 $0.07 4/15/2021160,000 shares $10,752.00 -14.5%N/A0.5 $0.07 3/31/2021187,200 shares $13,122.72 +10.1%N/A0.3 $0.07 3/15/2021170,000 shares $11,645.00 +6.3%N/A0.5 $0.07 2/26/2021160,000 shares $11,680.00 -34.0%N/A0.3 $0.07 2/12/2021242,400 shares $17,695.20 +25.9%N/A0.3 $0.07 1/29/2021192,600 shares $14,445.00 -54.3%N/A0.1 $0.08 1/15/2021299,400 shares $20,898.12 +76.1%N/A0.4 $0.07 12/31/2020160,500 shares $9,292.95 -46.4%N/A0.3 $0.06 12/15/2020299,400 shares $17,514.90 +76.1%N/A0.4 $0.06 11/30/2020170,000 shares $10,880.00 -1.4%N/A0.3 $0.06 11/15/2020172,400 shares $11,585.28 -46.8%N/A0.6 $0.07 10/30/2020324,100 shares $22,038.80 +23.8%N/A0.9 $0.07 10/15/2020261,700 shares $19,889.20 -44.8%N/A0.5 $0.08 9/30/2020473,700 shares $41,022.42 +194.6%N/A0.7 $0.09 9/15/2020160,800 shares $11,674.08 +0.2%N/A0.4 $0.07 8/31/2020160,500 shares $12,968.40 -42.0%N/A0.3 $0.08 8/14/2020276,700 shares $26,148.15 +3,493.5%N/A0.2 $0.09Nvidia is Pivoting to Solve Big Tech’s $1 Trillion Problem (Ad)Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …Find out details on these three critical Nvidia partners immediately. 7/31/20207,700 shares $553.63 -67.4%N/A0 $0.07 7/15/202023,600 shares $1,413.64 +81.5%N/A0.1 $0.06 6/30/202013,000 shares $585.00 +20.4%N/A0 $0.05 6/15/202010,800 shares $509.76 +2,060.0%N/A0 $0.05 5/29/2020500 shares $22.30 -80.0%N/A0 $0.04 5/15/20202,500 shares $105.25 +400.0%N/A0 $0.04 4/30/2020500 shares $21.00 No ChangeN/A0 $0.04 4/15/2020500 shares $24.15 -99.2%N/A0 $0.05 3/31/202061,000 shares $2,440.00 +634.9%N/A0.1 $0.04 3/13/20208,300 shares $498.00 +45.6%N/A0 $0.06 2/28/20205,700 shares $171.00 -79.2%N/A0 $0.03 2/14/202027,400 shares $1,096.00 +103.0%N/A0 $0.04 1/31/202013,500 shares $810.00 -2.2%N/A0 $0.06 1/15/202013,800 shares $924.60 -33.3%N/A0 $0.07 12/31/201920,700 shares $1,242.00 -95.9%N/A0 $0.06 PVCT Short Interest - Frequently Asked Questions What is Provectus Biopharmaceuticals' current short interest? Short interest is the volume of Provectus Biopharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of May 15th, investors have sold 500 shares of PVCT short. Learn More on Provectus Biopharmaceuticals' current short interest. Is Provectus Biopharmaceuticals' short interest increasing or decreasing? Provectus Biopharmaceuticals saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 500 shares, a drop of 99.6% from the previous total of 142,600 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Provectus Biopharmaceuticals' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Provectus Biopharmaceuticals: CytoDyn Inc. (0.47%), XOMA Co. (2.09%), ADC Therapeutics SA (1.36%), CorMedix Inc. (17.61%), Mersana Therapeutics, Inc. (7.35%), Vanda Pharmaceuticals Inc. (5.08%), Nature's Sunshine Products, Inc. (0.66%), Xeris Biopharma Holdings, Inc. (7.28%), Aquestive Therapeutics, Inc. (6.79%), Revance Therapeutics, Inc. (11.96%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.81 billion), Charter Communications, Inc. ($3.30 billion), Occidental Petroleum Co. ($3.10 billion), General Motors ($2.84 billion), Moderna, Inc. ($2.77 billion), AppLovin Co. ($2.22 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.16 billion), Tractor Supply ($2.12 billion), and Williams-Sonoma, Inc. ($2.12 billion). View all of the most shorted stocks. What does it mean to sell short Provectus Biopharmaceuticals stock? Short selling PVCT is an investing strategy that aims to generate trading profit from Provectus Biopharmaceuticals as its price is falling. PVCT shares are trading down $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Provectus Biopharmaceuticals? A short squeeze for Provectus Biopharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of PVCT, which in turn drives the price of the stock up even further. How often is Provectus Biopharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including PVCT, twice per month. The most recent reporting period available is May, 15 2024. More Short Interest Resources from MarketBeat Related Companies: CYDY Short Interest Data XOMA Short Interest Data ADCT Short Interest Data CRMD Short Interest Data MRSN Short Interest Data VNDA Short Interest Data NATR Short Interest Data XERS Short Interest Data AQST Short Interest Data RVNC Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (OTCMKTS:PVCT) was last updated on 6/3/2024 by MarketBeat.com Staff From Our PartnersTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBill Gates is all about this tiny $2 stockTimothy SykesBiden Nomination CANCELED?The Freeport SocietyExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsWrite this ticker symbol down…StocksToTradeShocking $16T Elon Musk Crypto LeakCrypto 101 MediaBiden replacement revealed?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Provectus Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.